{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:09:57Z","timestamp":1790770197936,"version":"4.1.0"},"reference-count":38,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,10,26]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>The intensified standard-of-care regimens for younger patients with MCL do not overcome the deleterious effects of TP53 mutations. MCLs with TP53 mutations should be considered for alternative frontline treatment.<\/jats:p>","DOI":"10.1182\/blood-2017-04-779736","type":"journal-article","created":{"date-parts":[[2017,8,17]],"date-time":"2017-08-17T20:50:28Z","timestamp":1503003028000},"page":"1903-1910","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":378,"title":["TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy"],"prefix":"10.1182","volume":"130","author":[{"given":"Christian W.","family":"Eskelund","sequence":"first","affiliation":[{"name":"Department of Hematology, Rigshospitalet, Copenhagen, Denmark;"},{"name":"Biotech Research and Innovation Centre, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Dahl","sequence":"additional","affiliation":[{"name":"Danish Cancer Society Research Center, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob W.","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rigshospitalet, Copenhagen, Denmark;"},{"name":"Biotech Research and Innovation Centre, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maj","family":"Westman","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, Rigshospitalet, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Kolstad","sequence":"additional","affiliation":[{"name":"Department of Oncology, Oslo University Hospital, Oslo, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone B.","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rigshospitalet, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen P.","family":"Montano-Almendras","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rigshospitalet, Copenhagen, Denmark;"},{"name":"Biotech Research and Innovation Centre, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Husby","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rigshospitalet, Copenhagen, Denmark;"},{"name":"Biotech Research and Innovation Centre, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catja","family":"Freiburghaus","sequence":"additional","affiliation":[{"name":"Department of Immunotechnology, Lund University, Lund, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ek","sequence":"additional","affiliation":[{"name":"Department of Immunotechnology, Lund University, Lund, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rigshospitalet, Copenhagen, Denmark;"},{"name":"Biotech Research and Innovation Centre, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Niemann","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rigshospitalet, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riikka","family":"R\u00e4ty","sequence":"additional","affiliation":[{"name":"Department of Hematology, Helsinki University Hospital, Helsinki, Finland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rigshospitalet, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian H.","family":"Geisler","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rigshospitalet, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette K.","family":"Andersen","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, Rigshospitalet, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Guldberg","sequence":"additional","affiliation":[{"name":"Danish Cancer Society Research Center, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Jerkeman","sequence":"additional","affiliation":[{"name":"Department of Oncology, Lund University Hospital, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Gr\u00f8nb\u00e6k","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rigshospitalet, Copenhagen, Denmark;"},{"name":"Biotech Research and Innovation Centre, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2019111905431616500_B1","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111905431616500_B2","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1182\/blood-2014-03-559930","article-title":"Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study","volume":"124","author":"Abrahamsson","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2019111905431616500_B3","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"issue":"10044","key":"2019111905431616500_B4","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"2019111905431616500_B5","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol"},{"issue":"13","key":"2019111905431616500_B6","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1200\/JCO.2013.52.2466","article-title":"Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network","volume":"32","author":"Hoster","year":"2014","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111905431616500_B7","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network","volume":"34","author":"Hoster","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111905431616500_B8","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.bbmt.2016.12.634","article-title":"Molecular monitoring after autologous stem cell transplantation and preemptive rituximab treatment of molecular relapse; results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with median follow-up of 8.5 years","volume":"23","author":"Kolstad","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2019111905431616500_B9","first-page":"4365","article-title":"Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants","volume":"93","author":"Be\u00e0","year":"1999","journal-title":"Blood"},{"issue":"19","key":"2019111905431616500_B10","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1182\/blood-2013-07-517177","article-title":"The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells","volume":"123","author":"Zhang","year":"2014","journal-title":"Blood"},{"issue":"13","key":"2019111905431616500_B11","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1182\/blood-2008-07-170183","article-title":"Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling","volume":"113","author":"Be\u00e0","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2019111905431616500_B12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"issue":"15","key":"2019111905431616500_B13","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.2016.70.7901","article-title":"New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"issue":"45","key":"2019111905431616500_B14","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Be\u00e0","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"2019111905431616500_B15","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1182\/blood-2011-11-391474","article-title":"Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma","volume":"119","author":"Kridel","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111905431616500_B16","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/bjh.12854","article-title":"SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study","volume":"166","author":"Nordstr\u00f6m","year":"2014","journal-title":"Br J Haematol"},{"key":"2019111905431616500_B17","year":"2011"},{"issue":"7","key":"2019111905431616500_B18","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1073\/pnas.0510441103","article-title":"Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma","volume":"103","author":"Greiner","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2019111905431616500_B19","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/0008-5472.CAN-09-3419","article-title":"Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma","volume":"70","author":"Fern\u00e0ndez","year":"2010","journal-title":"Cancer Res"},{"issue":"11","key":"2019111905431616500_B20","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1182\/blood-2004-10-3907","article-title":"Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome","volume":"105","author":"Rubio-Moscardo","year":"2005","journal-title":"Blood"},{"issue":"10","key":"2019111905431616500_B21","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/sj.leu.2401901","article-title":"Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin\u2019s lymphoma","volume":"14","author":"Gr\u00f8nbaek","year":"2000","journal-title":"Leukemia"},{"issue":"5","key":"2019111905431616500_B22","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","article-title":"High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma","volume":"126","author":"Delfau-Larue","year":"2015","journal-title":"Blood"},{"issue":"19","key":"2019111905431616500_B23","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1182\/blood-2013-12-541953","article-title":"Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM\/C in non-CR patients before transplant in mantle cell lymphoma","volume":"123","author":"Kolstad","year":"2014","journal-title":"Blood"},{"issue":"26","key":"2019111905431616500_B24","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1200\/JCO.2008.21.3116","article-title":"Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma","volume":"27","author":"Andersen","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111905431616500_B25","author":"Husby","year":"2015"},{"issue":"19","key":"2019111905431616500_B26","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","article-title":"Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study","volume":"120","author":"Xu-Monette","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111905431616500_B27","doi-asserted-by":"crossref","first-page":"a001008","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: origins, consequences, and clinical use","volume":"2","author":"Olivier","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"16","key":"2019111905431616500_B28","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1182\/blood-2013-01-478834","article-title":"The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma","volume":"121","author":"Meissner","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2019111905431616500_B29","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-\u03baB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat Med"},{"issue":"4","key":"2019111905431616500_B30","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.blre.2017.03.001","article-title":"p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell","volume":"31","author":"Tessoulin","year":"2017","journal-title":"Blood Rev"},{"issue":"24","key":"2019111905431616500_B31","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111905431616500_B32","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111905431616500_B33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111905431616500_B34","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111905431616500_B35","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111905431616500_B36","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3324\/haematol.2014.119115","article-title":"The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?","volume":"101","author":"Dreyling","year":"2016","journal-title":"Haematologica"},{"issue":"22","key":"2019111905431616500_B37","first-page":"128","article-title":"Ibrutinib-lenalidomide-rituximab in patients with relapsed\/refractory mantle cell lymphoma: first results from the nordic lymphoma group MCL6 (PHILEMON) phase II trial. [abstract]","author":"Jerkeman","year":"2016","journal-title":"Blood"},{"key":"2019111905431616500_B38","author":"Weigert","year":"2009"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/17\/1903\/1403034\/blood779736.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/17\/1903\/1403034\/blood779736.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T05:43:31Z","timestamp":1574142211000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/130\/17\/1903\/36514\/TP53-mutations-identify-younger-mantle-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,26]]},"references-count":38,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2017,10,26]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-04-779736","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.728772345.793548372","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,26]]}}}